January 31, 2022
Willkie advised Akorn in the sale of seven branded ophthalmic products to Théa.
On January 28, Willkie client Akorn Operating Company LLC, a specialty pharmaceutical company, announced that it entered into a definitive agreement to sell seven branded ophthalmic products to Théa, the leading independent European pharmaceutical group in ophthalmology.
The seven established brands included in the transaction are Zioptan®, AcellFX™, Betimol® , Cosopt®, Cosopt® PF, AzaSite® and Akten®.
Théa is an independent pharmaceutical company based in France specializing in the research, development and commercialization of eye-care products.
Akorn develops, manufactures and markets specialty pharmaceuticals, including prescription, consumer health and animal health products.
Willkie previously represented Akorn in the sale of its Consumer Health business to an affiliate of Prestige Consumer Health Inc.
The Willkie team was led by partners Russell Leaf, Thomas Mark and Tiffany Lee and counsel Jeffrey Daniel.
